Quantum-Si Hits Proteus Milestones but Faces Revenue Pressures Ahead of 2026 Launch
Event summary
- Quantum-Si achieved automated sequencing runs on integrated Proteus prototype systems, detecting 17 amino acids.
- First customer samples were sequenced on a Proteus prototype, with multiple customer posters and manuscripts released.
- Q1 2026 revenue was $258,000, with a gross margin of 29% and a net loss of $21.7 million.
- Company reiterated 2026 guidance: $1.0 million revenue, $98.0 million or less in adjusted operating expenses, and $93.0 million or less in total cash usage.
- Cash and cash equivalents totaled $190.4 million as of March 31, 2026, expected to support operations into Q2 2028.
The big picture
Quantum-Si is positioning itself as a leader in single-molecule protein sequencing, but its near-term revenue is being deliberately suppressed to prioritize the Proteus launch. The company's ability to manage cash burn while building market awareness will be critical as it transitions from development to commercialization. The proteomics market is highly competitive, and Quantum-Si's success will hinge on its ability to differentiate Proteus and secure early adopters.
What we're watching
- Commercialization Timing
- Whether Quantum-Si can sustain momentum and market awareness through roadshows ahead of the Proteus launch at the end of 2026.
- Financial Discipline
- How the company balances higher R&D spending with cost controls to extend its cash runway.
- Market Adoption
- The pace at which early access sites and customer evaluations will drive interest in the Proteus platform.
Related topics